An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection

Trial Profile

An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs RBX 2660 (Primary)
  • Indications Clostridium infections
  • Focus Therapeutic Use
  • Acronyms PUNCH Open Label
  • Sponsors Rebiotix
  • Most Recent Events

    • 08 Oct 2017 Primary endpoint of absence of CDI at 8 weeks from the last dose has been met, according to results presented at the IDWeek 2017.
    • 08 Oct 2017 Results presented at the IDWeek 2017
    • 04 Oct 2017 Data will be presented at the IDWeek 2017, according to a Rebiotix Inc. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top